

# Arrhythmias Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/AB8CDC02B389EN.html>

Date: March 2022

Pages: 66

Price: US\$ 2,000.00 (Single User License)

ID: AB8CDC02B389EN

## Abstracts

Arrhythmias Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 10 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 4 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Arrhythmias - Overview

Arrhythmias - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Arrhythmias - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Arrhythmias - Companies Involved in Therapeutics Development

Academic Pharmaceuticals Inc

Aetas Pharma Co Ltd

ARMGO Pharma Inc

Cardurion Pharmaceuticals LLC

Cynata Therapeutics Ltd

Espero BioPharma Inc

Galectin Therapeutics Inc

Gilead Sciences Inc

Jiangsu Kangyuan Pharmaceutical Co Ltd

LATITUDE Pharmaceuticals Inc

Les Laboratoires Servier SAS

LQT Therapeutics Inc

Nissan Chemical Corp

Orion Corp

SignPath Pharma Inc

Stablix Inc

Vera Therapeutics Inc

Arrhythmias - Drug Profiles

amiodarone - Drug Profile

Product Description

Mechanism Of Action

Antisense Oligonucleotides to Activate hERG1 for Arrhythmias - Drug Profile

Product Description  
Mechanism Of Action  
belapectin - Drug Profile  
Product Description  
Mechanism Of Action  
CYP-002 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
efsevin - Drug Profile  
Product Description  
Mechanism Of Action  
ESP-001 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Fusion Proteins for Arrhythmias - Drug Profile  
Product Description  
Mechanism Of Action  
Gene Therapy to Activate KCNQ1 for Arrhythmias - Drug Profile  
Product Description  
Mechanism Of Action  
Gene Therapy to Activate TBX5 for Arrhythmia and Ischemia - Drug Profile  
Product Description  
Mechanism Of Action  
GS-680 - Drug Profile  
Product Description  
Mechanism Of Action  
KN-93 - Drug Profile  
Product Description  
Mechanism Of Action  
M-201 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
MC-450 - Drug Profile  
Product Description  
Mechanism Of Action  
NTC-801 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Oligonucleotides to Activate KCNH2 for Romano-Ward Syndrome - Drug Profile

Product Description

Mechanism Of Action

History of Events

ORM-10103 - Drug Profile

Product Description

Mechanism Of Action

ORM-11372 - Drug Profile

Product Description

Mechanism Of Action

PP-1 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein for Myocardial Infarction and Ventricular Arrhythmia - Drug Profile

Product Description

Mechanism Of Action

SIPI-2011 - Drug Profile

Product Description

Mechanism Of Action

Small Molecules 1 for Arrhythmia - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Arrhythmia - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Arrhythmias - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize RyR2 for Heart Failure and Arrhythmias - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Block KCa3.1 for Arrhythmias - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules To Inhibit SGK-1 for Long QT Syndrome - Drug Profile

Product Description

Mechanism Of Action

soestelol - Drug Profile

Product Description

Mechanism Of Action

SPP-4040 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Arrhythmias - Dormant Projects

Arrhythmias - Discontinued Products

Arrhythmias - Product Development Milestones

Featured News & Press Releases

Jan 06, 2022: LQTT announces award by the European Joint Program for rare diseases for SGK1 inhibition as a novel therapeutic approach in LQTS

Oct 29, 2020: AnaBios and Orion publish scientific article describing novel cardiac compound

Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology

Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Arrhythmias, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Arrhythmias - Pipeline by Academic Pharmaceuticals Inc, 2022  
Arrhythmias - Pipeline by Aetas Pharma Co Ltd, 2022  
Arrhythmias - Pipeline by ARMGO Pharma Inc, 2022  
Arrhythmias - Pipeline by Cardurion Pharmaceuticals LLC, 2022  
Arrhythmias - Pipeline by Cynata Therapeutics Ltd, 2022  
Arrhythmias - Pipeline by Espero BioPharma Inc, 2022  
Arrhythmias - Pipeline by Galectin Therapeutics Inc, 2022  
Arrhythmias - Pipeline by Gilead Sciences Inc, 2022  
Arrhythmias - Pipeline by Jiangsu Kangyuan Pharmaceutical Co Ltd, 2022  
Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, 2022  
Arrhythmias - Pipeline by Les Laboratoires Servier SAS, 2022  
Arrhythmias - Pipeline by LQT Therapeutics Inc, 2022  
Arrhythmias - Pipeline by Nissan Chemical Corp, 2022  
Arrhythmias - Pipeline by Orion Corp, 2022  
Arrhythmias - Pipeline by SignPath Pharma Inc, 2022  
Arrhythmias - Pipeline by Stablix Inc, 2022  
Arrhythmias - Pipeline by Vera Therapeutics Inc, 2022  
Arrhythmias - Dormant Projects, 2022  
Arrhythmias - Dormant Projects, 2022 (Contd..1)  
Arrhythmias - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Arrhythmias, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Number of Products by Top 10 Targets, 2022  
Number of Products by Stage and Top 10 Targets, 2022  
Number of Products by Top 10 Mechanism of Actions, 2022  
Number of Products by Stage and Top 10 Mechanism of Actions, 2022  
Number of Products by Routes of Administration, 2022  
Number of Products by Stage and Routes of Administration, 2022  
Number of Products by Molecule Types, 2022  
Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Arrhythmias Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/AB8CDC02B389EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB8CDC02B389EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

